Novartis | NOVN - Beneficio Bruto En Ventas

Precio De Mercado
117.54
Cambio Diario
-1.96 -1.64%
Mensual
-7.05%
Anual
17.80%
Q1 Expectativa
118.31




Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 10.47B 605M 2025-09
Alcon AG USD 1.52B 58M 2025-12
Almirall EUR 429.87M 180.02M 2025-12
Amgen USD 6.48B 307M 2025-09
AstraZeneca USD 12.39B 5M 2025-12
Autolus Therapeutics Ltd USD -7.45M 3.93M 2025-09
Bayer EUR 5.35B 1.02B 2025-09
Biogen USD 1.65B 34.6M 2025-12
Bristol-Myers Squibb USD 8.79B 110M 2025-09
Eli Lilly USD 14.59B 1.48B 2025-09
Fresenius EUR 1.51B 214M 2025-12
Fresenius Medical Care EUR 1.39B 147M 2025-12
Galapagos EUR -13.57M 74.82M 2025-09
Genmab DKK 868M 195M 2025-06
Gilead Sciences USD 6.31B 106M 2025-12
GlaxoSmithKline GBP 6.18B 106M 2025-12
GRIFOLS EUR 743.8M 49.13M 2025-06
Hikma Pharmaceutical USD 362.5M 329.5M 2025-06
J&J USD 16.6B 118M 2025-12
Lonza CHF 1.29B 248M 2025-06
Merck EUR 2.96B 252M 2025-12
Merck USD 13.42B 431M 2025-09
Novartis USD 10.82B 695M 2025-09
Novartis USD 10.82B 694M 2025-09
Novo Nordisk DKK 64.01B 1.19B 2025-06
Orion EUR 508.7M 254.5M 2025-12
Pfizer USD 3.54B 7.61B 2025-09
Philips EUR 2.29B 377M 2025-12
Recordati EUR 432.41M 8.56M 2025-09
Regeneron Pharmaceuticals USD 3.3B 67M 2025-12
Roche Holding CHF 22.09B 10.04B 2025-12
Sanofi EUR 8.45B 1.31B 2025-12
UCB EUR 2.46B 520M 2024-12